Viewing Study NCT05951959


Ignite Creation Date: 2025-12-24 @ 2:47 PM
Ignite Modification Date: 2026-01-28 @ 10:20 PM
Study NCT ID: NCT05951959
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-10-21
First Post: 2023-06-05
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
Sponsor: AstraZeneca
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Mantle Cell Lymphoma (MCL) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Mantle Cell Lymphoma View
None Lymphoma View
None Acalabrutinib View
None Venetoclax View
None Rituximab View